-
Leukemia: Prognosis for early relapse after autologous stem cell transplantation in Hodgkin lymphoma patients has improved in recent years
Time of Update: 2022-05-17
C Cumulative incidence of checkpoint inhibitor (CPI) use according to year of relapse in adult patients relapsed after autologous sct in patients with relapsed/refractory classic HL following first-line therapy .
-
Hematology: Platelet-to-leukocyte ratio is an independent prognostic predictor in acute myeloid leukemia
Time of Update: 2022-05-17
FLT3 NPM1, DNMT3A IDH1 IDH2 ASXL1 TET2Overall, this study found that the platelet to white blood cell count (PWR) ratio could be used as an independent predictor of overall survival and event-free survival in CN-AML patients .
-
NEJM: Efficacy of oral rizabrutinib in the treatment of immune thrombocytopenia
Time of Update: 2022-05-15
Rizabrutinib is an oral, reversible covalent inhibitor of tyrosine kinases that increases platelet counts in patients with immune .
https:// Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia leave a message here
-
AJH: Prediction of survival and association of characteristics with intensive chemotherapy in acute myeloid leukemia
Time of Update: 2022-05-15
In the training cohort, multivariate analysis identified 12 consistent poor prognostic variables independently associated with poorer survival: older age, treatment-related myeloid neoplasms, poorer performance status, cardiac comorbidities, leukocytosis, anemia , thrombocytopenia, elevated creatinine and lactate dehydrogenase, cytogenetic abnormalities, and infection at diagnosis , except unexplained fever .
-
All you want to know about coagulation factors is here
Time of Update: 2022-05-15
Factor IX : C decreased, seen in hemophilia C , liver disease, vitamin K deficiency, disseminated intravascular coagulation, oral anticoagulants, etc.
Factor IX : C decreased, seen in hemophilia C , liver disease, vitamin K deficiency, disseminated intravascular coagulation, oral anticoagulants, etc.
-
NEJM: Efficacy of Mitapivat in the Treatment of Pyruvate Kinase Deficiency (ACTIVATE Trial)
Time of Update: 2022-05-15
The study's secondary efficacy endpoints were mean changes from baseline in hemoglobin levels, markers of hemolysis and hematopoiesis, and changes from baseline in patient-reported outcomes specific for pyruvate kinase deficiency in both groups at week 24 .
-
Haematologica: Leukemia-inducing syndromes are major cause of hereditary cytopenias in children
Time of Update: 2022-05-15
Methods: The study included children with persistent cytopenia, myelodysplastic syndrome, aplastic anemia, or suspected hereditary bone marrow failure syndrome who were referred to all pediatric blood centers in Israel between 2016-2019 Genetic evaluation .
-
Acta Haematol: Unique mechanism of IgM antibody-mediated acquired von Willebrand syndrome and successful treatment of recombinant von Willebrand factor in one patient
Time of Update: 2022-05-15
There were no reports of bleeding in the patient's past or family history, and laboratory tests showed decreased VWF antigen and VWF activity .
There were no reports of bleeding in the patient's past or family history, and laboratory tests showed decreased VWF antigen and VWF activity .
-
BJH: Persistent fatigue symptoms, neuropathy, and role dysfunction in survivors of indolent non-Hodgkin lymphoma: a longitudinal PROFILES registry study
Time of Update: 2022-05-15
There are no longitudinal neuropathy data in the normal population, so this neuropathy score is based on cross-sectional measurements in 2014, CLL, chronic lymphocytic leukemia; FL, follicular lymphoma; iNHL, indolent non-Hodgkin lymphoma; SLL, small lymphocytic lymphomaScores remained relatively stable with no clinically relevant changes for up to 10 years after diagnosis .
-
Blood: Zinc promotes regeneration and recovery of the immune system after bone marrow transplantation
Time of Update: 2022-05-15
This study further revealed that after hematopoietic stem cell transplantation, zinc accumulated in thymocytes is released into the extracellular environment, and stimulates endothelial cells to produce the regenerative factor BMP4 through the cell surface receptor GPR39, thereby promoting thymic tissue regeneration .
-
Haematol: Treatment-free remission in patients with chronic myeloid leukemia receiving first-line nilotinib: a 10-year follow-up study
Time of Update: 2022-05-15
Nilotinib (NIL) is a tyrosine kinase inhibitor (TKI) initially shown to be effective in chronic phase (CP) chronic myeloid leukemia (CML) resistant or intolerant patients twice daily 400mg, well tolerated .
-
J Thromb Haemost: Analysis of risk factors for bleeding in patients with hemophilia A and B
Time of Update: 2022-05-15
The aim of this study was to systematically review the literature on risk assessment models (RAMs) and risk factors for regular bleeding prevention with PWH .
The purpose of this study was to systematically review the literature on risk assessment models (RAMs) and risk factors for regular bleeding prevention with PWH .
-
Neurology: Should dual antiplatelet therapy be switched to cilostazol after 2 weeks?
Time of Update: 2022-05-15
Compared with aspirin (ASA) monotherapy, dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel (ASA+CLO) reduces the risk of early recurrent stroke after minor ischemic stroke or high-risk TIA, but the first The effect of DAPT on stroke risk reduction gradually diminished after one month, and from then on also increased the risk of major bleeding (vs ASA) .
-
BJH: Outcomes of Daratumumab in Multiple Myeloma: A Retrospective Cohort Study from the Canadian Myeloma Study Group Database
Time of Update: 2022-05-15
D: dexamethasone, DARA: daratumumab, P: prednisone, Pom: pomalidomide, R: lenalidomide, V: bortezomibFigure 1 : Survival outcomes for DARA-based treatment lines: (A) progression-free survival; (B) overall survival .
-
J Clin Oncol: Efficacy and safety of sorafenib combined with standard chemotherapy in children with FLT3/ITD+ acute myeloid leukemia
Time of Update: 2022-05-15
It is feasible and safe to add sorafenib to routine chemotherapy in children with HAR FLT3/ITD positive acute myeloid leukemia, and it is expected to improve the clinical prognosis of children .
-
Dangerous, a battle of "white" and "bacteria" in the blood!
Time of Update: 2022-05-08
【Case History】【Case History】On the morning of March 6th, a colleague on the evening shift informed him that he had a critically low white blood cell count last night, and he looked at what was abnormal in the blood smear .
-
Express Advances Innovative Treatments for Multiple Myeloma, Sanofi and Blackstone Reach 300 Million Euro Partnership
Time of Update: 2022-04-30
Under the terms of the collaboration agreement, Blackstone Life Sciences will pay up to €300 million to accelerate a global pivotal research and clinical development program to evaluate a subcutaneous formulation of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma (MM) patients .
-
2022 EBMT Voice of China Universal anti-CD123 CAR-γδ T cells combined with donor lymphocyte infusion in the treatment of patients with relapsed AML after allo-HSCT
Time of Update: 2022-04-30
The team of Professor Jiang Erlie from the Hospital of Hematology, Chinese Academy of Medical Sciences applied universal anti-CD123 CAR-γδT cells combined with DLI to a patient with AML who had relapsed after allo-HSCT, and evaluated the efficacy and safety .
-
Tisagenlecleucel is effective and safe in adult patients with relapsed/refractory primary CNS lymphoma
Time of Update: 2022-04-30
Real-world data from the International Center for Blood and Bone Marrow Transplantation Study (CIBMTR) demonstrate a lower incidence of severe immune effector cell-associated neurotoxicity syndrome (ICANS) in systemic lymphoma with Tisagenlecleucel, and results from a previous retrospective study demonstrating Tisagenlecleucel Safety and efficacy in secondary central nervous system lymphoma .
-
Experts explore the "Olympic" Jin Zhengming and Professor Wang Li: After a thousand sails, the future can be expected, experts share the time memory of indolent lymphoma
Time of Update: 2022-04-30
In the exploration of chemotherapy drugs, rituximab combined with bendamustine can effectively improve the treatment effect of patients, reduce recurrence, and in terms of adverse reactions, it can significantly reduce myelosuppression and cardiotoxicity compared with the R-CHOP regimen.
